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Summary
Objective: To characterize the effects of nimesulide (NIM) on basal and induced cyclo-oxygenase-2 (COX-2) gene expression in human
synovial fibroblasts (HSF) and to define the intracellular mechanisms that mediate the changes in COX-2 expression and synthesis in
response to the drug.
Design: HSF were incubated with NIM and NS-398 (0, 0.03, 0.3, 3 g/ml) in the absence or presence of the COX-2 inducers interleukin-1
(IL-1) or endotoxin (LPS). Treated cells were analysed for COX-2 mRNA and protein by Northern and Western blotting analysis,
respectively. Putative transcriptional, post-transcriptional, and signaling effects of NIM on basal and induced-COX-2 expression were
investigated by human COX-2 promoter studies, calcium studies, reactive oxygen species (ROS) evaluations, electrophoretic mobility shift
analysis (EMSA) and half-life studies of COX-2 mRNA.
Results: NIM inhibited IL-1-induced COX-2 expression and protein at sub and therapeutic concentrations (0.03–0.3 g/ml) while the
non-specific NSAID, naproxen, did not. Both drugs suppressed PGE2 release by about 95%. NIM had no effect on (1) IL-1-induced
increases in NF-B or c/EBP signaling, or (2) human COX-2 promoter activity. Stability of induced COX-2 mRNA was unaffected by NIM
treatments. Pre-treatment of cells with O2 radical scavengers (e.g. PDTC) or with Ca+ + channel blockers (e.g. verapamil) had a modest
effect on IL-1-induced COX-2 expression. NIM blocked ionomycin+thapsigargin and H2O2-induced increases in COX-2 protein synthesis.
Conclusion: NIM inhibits cytokine-induced COX-2 expression and protein at sub and therapeutic concentrations. At least part of this activity
may be the result of NIM inhibition of calcium and/or free radical generation induced by cytokines. © 2001 OsteoArthritis Research Society
International
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Nimesulide (NIM, 4-nitro-2-phenoxymethanesulfonanilide),
is a preferential cyclo-oxygenase-2 (COX-2) inhibitor1–3
with marked biological effects in several in vivo models of
inflammation4,5. It is believed that the molecular basis for
the therapeutic actions of NIM lies in the drug’s ability to
inhibit the release of inflammatory prostaglandins by
specifically suppressing cyclo-oxygenase-2 (COX-2)
activity3. However, a number of studies suggest that in
addition to the well-described inhibition of prostaglandin
synthesis, NIM has pleiotropic effects particularly in terms
of neutrophil function. For example, the drug inhibits the
neutrophil respiratory burst, integrin-mediated adherence
and synthesis of platelet-activating factor (PAF)6–8. Many of
these actions have been attributed to the ability of NIM to332increase cellular levels of cyclic AMP (cAMP) by inhibiting
cAMP-dependent phosphodiesterase type IV6,7.
Using human osteoarthritic synovial fibroblasts in cul-
ture, we showed9 that NIM and naproxen (NAP), at thera-
peutic doses, reduces the synthesis of urokinase (uPA) and
interleukin-6 (IL-6), while increasing the production of plas-
minogen activator inhibitor-1 (PAI-1). Furthermore, it was
demonstrated that NIM decreases matrix metalloprotease
(MMP) synthesis by cartilage in vitro10. Taken together,
these results suggest that the drug can inhibit cartilage
catabolism through mechanisms not associated with the
inhibition of COX-2 activity and eicosanoid release.
Recently, we demonstrated that NIM stimulates hyperphos-
phorylation of the glucocorticoid receptor (GR) in human
synovial fibroblasts resulting in an activation of the GR in
terms of glucocorticoid response element (GRE) binding
and transactivation of GR-sensitive promoters (e.g. mouse
mammary tumor virus long terminal repeat, MMTV-
LTR)11.
The aim of the present study was to determine whether a
separate class of NSAIDs, namely specific COX-2 inhibi-
tors, could effect changes in COX-2 expression in connec-
tive tissue cells. We show that NIM down-regulates IL-1
and LPS (endotoxin)-induced COX-2 mRNA expression
and protein synthesis in human osteoarthritis (OA)-affected
synovial fibroblasts at therapeutically relevant doses in
addition to its well-described suppression of PGE2 release.
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induced changes in calcium flux and/or metabolism of
reactive oxygen species (ROS).
Materials and methods
CHEMICALS
Nimesulide (NIM), [N-(4-nitro-2-phenoxyphenyl)-
methanesulfonamide], was kindly provided by Helsinn
Healthcare SA (Lugano, Switzerland). Crystalline dexam-
ethasone (DEX) [9-fluoro-11, 17, 21-trihydroxy-16-
methylpregna-1,4, diene-3, 20-dione], sodium fluoride,
sodium ortho-vanadate, okadaic acid, leupeptin, aprotinin,
pepstatin, phenylmethylsulphonylflouride (PMSF), dithioth-
reitol (DTT), and bovine serum albumin (BSA) were from
Sigma-Aldrich Canada (Oakville, Ontario, Canada).
Naproxen and NS-398 were obtained from Cayman
Chemical Co. (Ann Arbor, MI), while nifedipine, verapamil
and 1-pyrrolidinecarbodithioic acid (PDTC) were purchased
from Calbiochem (La Jolla, CA). Sodium dodecyl sul-
fate (SDS), acrylamide, bis-acrylamide, ammonium
persulfate, and Bio-Rad protein reagent originated from
Bio-Rad Laboratories (Richmond, CA). Tris, EDTA, MgCl2,
CaCl2, chloroform, dimethylsulphoxide (DMSO), formalde-
hyde and formamide are products of Fisher Scientific
(Nepean, Ontario, Canada). Human recombinant IL-1
(rhIL-1) and LPS were obtained from Genzyme Corpora-
tion (Cambridge, MA). Dulbecco’s Modified Eagle Medium
(DMEM), phosphate-free and phenol-red free DMEM,
Trizol reagent, heat inactivated fetal calf serum (FCS), and
an antibiotic mixture [10 000 units of penicillin (base),
10 000 g of streptomycin (base)] were products of Gibco
BRL-Life Technologies (Burlington, Ontario, Canada).SPECIMEN SELECTION AND SYNOVIAL FIBROBLAST CULTURES
Synovial lining cells (human synovial fibroblasts, HSF)
were isolated from OA and rheumatoid arthritis (RA)
patients undergoing arthroplasty who were diagnosed
based on the criteria developed by the American College of
Rheumatology Diagnostic Subcommittee for OA/RA.
Human synovial fibroblasts were released by sequential
enzymatic digestion with 1 mg/ml pronase (Boehringer
Mannheim Canada, Laval, Quebec, Canada) for 1 h, fol-
lowed by 6 h with 2 mg/ml collagenase (type IA, Sigma) at
37°C in DMEM supplemented with 10% heat inactivated
FCS, 100 units/ml penicillin and 100 g/ml streptomy-
cin12,13. Released HSF were incubated for 1 h at 37°C in
tissue culture flasks (Primaria No. 3824, Falcon, Lincoln
Park, NJ) allowing the adherence of non-fibroblastic cells
possibly present in the synovial preparation. In addition,
flow cytometric analysis (Epic II, Coulter, Miami, FL), using
the anti-CD14 (fluorescein isothiocyanate, FITC) antibody,
was conducted to confirm that no monocytes/macrophages
were present in the synoviocyte preparations12. The cells
were seeded in tissue culture flasks and cultured until
confluence in DMEM supplemented with 10% FCS and
antibiotics at 37°C in a humidified atmosphere of 5%
CO2/95% air. The cells were incubated in fresh serum-free
medium for 24 h before the experiments and only second
or third passaged HSF were used.PREPARATION OF CELL EXTRACTS AND WESTERN BLOTTING
Fifty to 100 g of cellular extract (in RIPA buffer; 50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1 mM PMSF,10 g/ml each of aprotinin, leupeptin, and pepstatin, 1%
NP-40, 1 mM sodium orthovanadate, and 1 mM NaF) from
control and treated HSF were subjected to SDS-PAGE
through 10% gels (final concentration of acrylamide) under
reducing conditions, and transferred onto nitrocellulose
membranes (Amersham Pharmacia Biotech, Baie d’Urfe´,
Que´bec, Canada). Following blocking (with 5% BLOTTO)
and washing, the membranes were incubated for either 2 h
at RT, or overnight at 4°C, with primary antibodies (see
below) in TTBS containing 0.25% BLOTTO. Second anti-
rabbit antibody-HRP conjugates (1:2000 dilution) were sub-
sequently incubated with membranes for 1 h at RT, and
then washed extensively for 30–40 min with TTBS, and a
final rinsing with TBS at RT. Following incubation with an
ECL chemiluminescence reagent (Amersham Pharmacia
Biotech), membranes were prepared for autoradiography
and exposed to Kodak X-Omat film (Kodak, Rochester,
NY), then subjected to densitometric analysis for semi-
quantitative measurements. The antibody used was the
polyclonal antihuman COX-2 (Cayman Chemical Co., Ann
Arbor, MI, 1:5000 dilution).NORTHERN BLOT ANALYSIS OF MRNA
Total cellular RNA was isolated (1×106 cells=10–20 g
RNA) using the Trizol (Gibco BRL-Life Technologies) re-
agent. Generally, 10–15 g of total RNA were resolved
on 0.9% agarose-formaldehyde gel and transferred to
Hybond-NY nylon membranes (Amersham Pharmacia
Biotech) in 20×SSC buffer, pH 7 by vacuum blotting. After
pre-hybridization for 24 h, hybridizations were carried out at
50–57°C for 24–36 h, followed by high-stringency washing.
The following probes, labeled with digoxigenin (DIG)-dUTP
by random priming, were used for hybridization: human
COX-2 cDNA (1.8 kb, Cayman Chemical Co.) was cloned
into the EcoRV site of pcDNA 1 (Invitrogen, Carlsbad, CA)
and released by PstI and XhoI digestion. A 780 bp PstI/
XbaI fragment from GAPDH cDNA (1.2 kb; American Type
Culture Collection, Rockville, MD) was subcloned into
pGEM-3Z vector (Promega Corp., Madison, WI) and a
cRNA probe were synthesized after linearization with PstI.
This latter probe served as a control of RNA loading as
GAPDH is constitutively expressed. All blots were sub-
jected to densitometric analysis for semiquantitative
measurements.EXTRACTION OF NUCLEAR PROTEINS AND EMSA EXPERIMENTS
Confluent HSF in four-well cluster plates (3–5×106 cells/
well) from control and treated cells were carefully scraped
into 1.5 ml of ice-cold PBS and pelleted by brief centrifu-
gation. Nuclear extracts were prepared as previously
described11.
Double-stranded oligonucleotides containing consensus
sequences (Santa Cruz Biotechnology, Santa Cruz, CA)
were end-labeled with [-32P]ATP using T4 polynucleotide
kinase (Promega). The sense sequences of the oligos
tested were as follows: NF-B; 5′-AGT TGA GGG GAC
TTT CCC AGG C-3′: c/EBP-COX-2; 5′-CAC CGG GCT
TAC GCA ATT TTT TTA A-3′. Binding buffer consisted of
10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM DTT,
0.5 mM EDTA, 1 mM MgCl2, 4% glycerol and 2.5 g poly(dI-dC). Binding reactions were conducted with 15 g of
nuclear extract and 100 000 cpm of 32P-labeled oligonucle-
otide probe at 22°C for 20 min in a final volume of 10 l.
334 H. Fahmi et al.: Nimesulide inhibits IL-1-induced COX-2 expressionBinding complexes were resolved by non-denaturing poly-
acrylamide gel electrophoresis through 6% gels in a Tris-
borate buffer system, after which the gels were fixed, dried
and prepared for autoradiography.MEASUREMENT OF PGE2
Prostaglandin E2 was measured in conditioned medium
by ELISA, according to the manufacturer’s instructions
(R&D Systems, Minneapolis, MN). The detection limit and
sensitivity was 39 pg/ml.Results
TIME-COURSE AND DOSE–RESPONSE ACTIVATION OF COX-2 mRNA
AND PROTEIN SYNTHESIS BY IL-1 AND LPS IN HUMAN SYNOVIAL
FIBROBLASTS
To establish the appropriate experimental conditions to
study the effects of NIM on induced COX-2 expression, we
determined temporal and concentration optimums for the
inductive process. Western analysis revealed that the EC50
value for the induction of COX-2 protein synthesis was as
follows: IL-1 (98 pg/ml or 9.8 U/ml, CV=4.1%) [Fig. 1(A)].
LPS (endotoxin) weakly stimulated COX-2 protein syn-
thesis and the effect was not saturable being directly
proportional to the concentration of LPS up to 100 g/ml
[Fig. 1(B)]. As such in subsequent experiments with NIM,
IL-1 was used at 98 pg/ml and, where indicated, we added
LPS at 20 g/ml since it gave a 50% response albeit under
nonsaturating conditions.
Time course studies indicated that maximum stimulation
of COX-2 mRNA by IL-1 occurred at between 1–8 h
followed by a gradual decline. The COX-2 protein levels
peaked somewhat later than mRNA at 4–8 h with the same
slow cellular depletion that characterized COX-2 mRNA
[Fig. 1(C)].Fig. 1. Dose-dependent activation of COX-2 protein synthesis by
IL-1 (A) and LPS (B) and time course (C) of IL-1 stimulation of
COX-2 mRNA and protein in human synovial fibroblasts. Confluent
synovial fibroblasts (1.2×106 cells in six-well plates) were pre-
incubated for 24 h in DMEM supplemented with 1% FCS plus
antibiotics at 37°C in order to synchronize the cell population. Cells
were then treated with increasing concentrations of (A) IL-1
(0–500 U/ml) or (B) LPS (0–100 g/ml) for 16 h at 37°C or (C) in
the presence of vehicle (control) or IL-1 (10 U/ml) for 5, 15,
30 min, 1, 2, 4, 8, 16, 24 h at 37°C. Monolayers were extracted for
protein and 50 g were analysed by Western analysis for COX-2
protein. Alternatively, RNA was extracted and 10 g were analysed
for COX-2 mRNA by Northern analysis using a complementary
DIG labeled cDNA probe for COX-2 and cRNA probe GAPDH (as
a control for loading and mRNA recovery) as described in the
Materials and methods section. Representative blots are shown in
A, B, C. Densitometric and mathematical analysis of the data
(N=3) yielded the following equation: y=2617+9461 log (x),
r=0.97, concentration of IL-1, x-axis vs optical density, y-axis:
y=1959+94.7x, r=0.999, concentration of LPS, x-axis vs optical
density, y-axis. Densitometric ratio COX-2/GAPDH mRNA (mean
of two experiments, CV<11.3%) is graphically illustrated.EFFECT OF NIM ON BASAL AND INDUCED COX-2 mRNA
EXPRESSION AND PROTEIN
NIM inhibited IL-1-induced COX-2 expression and pro-
tein at all concentrations (0.03, 0.3, 3.0 g/ml) (see Fig. 2)
and similar results were obtained with the analog NS-398.
Temporal analysis revealed that the inhibitory effect of NIM
was at its most robust at 16–24 h (data not shown).
Previous studies in our laboratory revealed that NIM and a
prototypic non-specific COX inhibitor, naproxen, exhibited
differential effects in terms of the transactivation of the
glucocorticoid receptor11. In the present study, naproxen
(NAP), at a pharmacologically relevant concentration, had
no effect on IL-1-induced COX-2 expression [Fig. 3(A)]. A
profile of PGE2 release in the presence of NIM and NAP is
shown in Fig. 3(B). As expected, the prototypic antiinflam-
matory steroid dexamethasone (1 mol/l) also inhibited
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To test whether the effects of NIM on COX-2 expression
were promoter based, we transfected HSF with a human
COX-2 promoter construct containing at least 1.8 kb of the
5′ flanking promoter region of the COX-2 gene containing
two NF-B and AP-2 sites, a c/EBP, Ets-1 and CRE motif,
and three Sp-1 sites upstream from the 5′-tataa-3′ box.
NIM, at 0.03, 0.3, and 3 g/ml, had no effect on either basal
or IL-1-induced COX-2 promoter activity in transfected
HSF (Fig. 5).Fig. 2. Effect of NIM and NS-398 on IL-1-induced COX-2 mRNA
expression and protein synthesis in human synovial fibroblasts.
Confluent synovial fibroblasts were incubated with vehicle or IL-1
(10 U/ml) in the absence or presence of 0.03, 0.3, 3 g/ml of NIM
and NS-398 for 16 h at 37°C. Monolayers were either extracted for
protein and 50 g were analysed by Western analysis for COX-2
protein or RNA was extracted and 10 g were analysed for COX-2
mRNA by Northern analysis. A complementary DIG labeled cDNA
probe for COX-2 and cRNA probe GAPDH (as a control for loading
and mRNA recovery) were employed as described in the Materials
and methods section. Ratio COX-2/GAPDH mRNA (mean of three
experiments, CV<15.6%), determined by densitometric analysis, is
shown graphically.Fig. 3. Effect of NIM and naproxen on IL-1-induced COX-2 mRNA
expression, protein synthesis (A) and PGE2 release (B) in human
synovial fibroblasts. Confluent synovial fibroblasts were incubated
with vehicle or IL-1 (10 U/ml) in the absence or presence of
0.003, 0.03, 0.3, 3 g/ml of NIM and 90 g/ml of naproxen (NAP)
for 16 h at 37°C. Monolayers were either extracted for protein and
50 g were analysed by Western analysis for COX-2 protein or
RNA was extracted and 10 g were analysed for COX-2 mRNA by
Northern analysis as described in the Materials and methods
section. The amount of PGE2 released into the medium was
measured by ELISA (N=3).EFFECT OF NIM ON IL-1 INDUCTION OF C/EBP AND NF-B
OLIGONUCLEOTIDE NUCLEAR BINDING PROTEINS
Considerable evidence has accrued demonstrating that
c/EBP and NF-B are two important transacting factors thatIL-1/LPS-induced COX-2 expression and synthesis (data
not shown). The inhibition of IL-1 induced COX-2 mRNA
expression at lower doses of NIM was not the result of
changes in the half-life of the COX-2 mRNA (Fig. 4).
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ant increase in COX-2 gene transcription and mRNA
accumulation14–17. As shown in Fig. 6, IL-1 (10 U/ml)
strongly induced both c/EBP and NF-B oligonucleotide
binding but NIM, at a concentration (0.3 g/ml) that inhibits
COX-2 expression, had no effect on the level of nuclear
protein binding to the 32P-oligonucleotides tested.Fig. 4. Effect of NIM on IL-1-induced COX-2 mRNA half-life in
human synovial fibroblasts. Confluent synovial fibroblasts were
incubated with vehicle or IL-1 (10 U/ml) for 4 h after which time
the cells were transcriptionally arrested with actinomycin D (1 g/
ml). Arrested cells were further incubated with vehicle or NIM
(0.3 g/ml) for 4, 16 and 24 h. Monolayers were extracted for RNA
and 10 g were analysed for COX-2 mRNA by Northern analysis.
A complementary DIG labeled cDNA probe for COX-2 and cRNA
probe GAPDH (as a control for loading and mRNA recovery) were
employed as described in Materials and methods. Densitometric
ratio of COX-2/GAPDH mRNA (mean of two experiments, CV
<3.9%) is illustrated graphically.Fig. 5. Effect of NIM on basal and IL-1 induced human COX-2
promoter activity. Cells were co-transfected with 1 g of the COX-2
promoter-LUC plasmid together with 0.5 g of pCMV -Gal (control
for transfection efficiency) as described in the Materials and
Methods section. The transfected cells were then incubated with
IL-1 (10 U/ml) alone or with NIM (0.03, 0.3, 3 g/ml) for 16 h at
37°C. Cells were then lysed and analysed for Luciferase (LUC)
and -galactosidase. LUC activity (N=2 determinations in
duplicate).Fig. 6. Effect of NIM on IL-1 induced c/EBP and NF-B oligo-
nucleotide nuclear binding proteins. Confluent synovial fibroblasts
were incubated with vehicle or Il-1 (10 U/ml) in the absence or
presence of NIM (0.3 g/ml), after which time nuclear extracts
were prepared. Gel shift binding reactions were conducted as
described in the Materials and methods section as follows: upper
panel; lane 1, control nuclear protein extracts+32P-labeled NF-B
oligonucleotide; lane 2, IL-1 stimulated nuclear extracts+32P-
labeled NF-B oligonucleotide; lane 3, IL-1+NIM treated nuclear
extracts+32P-labeled NF-B oligonucleotide; lane 4, L-1 stimu-
lated nuclear extracts+32P-labeled NF-B oligonucleotide with
five-fold excess radioinert NF-B oligonucleotide competitor.
Middle panel; lanes 5–8 represent the same experiment as lanes
1–4 but 32P-labeled c/EBP oligonucleotide was used.REACTIVE OXYGEN SPECIES (ROS), CALCIUM AND IL-1
INDUCTION OF COX-2 PROTEIN SYNTHESIS
IL-1 induces a number of genes indirectly through
short-lived reactive oxygen species (ROS) intermediaries
that include NO, H2O2, and superoxide anion18,19. In
human chondrocytes, IL-1 induced COX-2 expression
occurs, in part, by changes in cellular calcium metab-
olism20,21. IL-1-induced COX-2 protein was modestly sup-
pressed (compared to NIM), by the L-type calcium channel
blockers nifedipine and verapamil, with verapamil being
more efficacious than nifedipine [Fig. 7(A)]. Increasing the
intracellular levels of calcium through the use of the calcium
ionophore ionomycin, in combination with endoplasmic
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increase in COX-2 protein synthesis [compare lane 1 vs
lane 7, Fig. 7(B)]. This induction was inhibited by NIM
(0.3 g/ml) (compare lane 7 vs lane 8). Combining IL-1
with ionomycin and thapsigargin slightly enhanced COX-2
synthesis over ionomycin and thapsigargin alone (lane 2 vs
lane 9).
In an attempt to verify whether COX-2 induction by IL-1
is dependent on ROS in HSF, we treated cells with IL-1 in
the presence of the ROS scavenger PDTC (100 mol/l). As
shown in Fig. 7(B) (lane 2 vs lane 3), PDTC had a modest
effect on IL-1 induced COX-2 protein synthesis. Induction
of COX-2 by H2O2 (100 nmol/l) was reversed by PDTC and
NIM (lanes 4, 5 and 6). Combining PDTC with verapamil
had a slight additive effect in terms of the suppression of
induced COX-2 protein synthesis [Fig. 7(C), lanes 4, 5
and 6].sulfonamide class (NIM, NS-398), owe their therapeutic
efficacy in part to what we have defined as ‘allo-effects’.
The latter consist of activities other than the simple inhi-
bition of cyclo-oxygenase activity and release of prosta-
glandins and can be either promoter-based, modulation of
signaling cascades, suppression of free-radical generation
or modulation of second messengers (e.g. calcium flux).
Examples of ‘allo-effects’ would be changes in the expres-
sion level of target genes (e.g. COX-2), or the recently
reported activation of ligand inducible nuclear receptor
systems (e.g. glucocorticoid receptor) with the resultant
induction of target gene promoters11.
Interleukin-1 induces COX-2 gene expression in human
connective tissue cells by binding to a specific cell-surface
receptor (IL-1RI) with the resultant activation of a signaling
cascade(s) (e.g. IL-1RI/IL-1RacProtein/IRAK1/2/TRAF6/
NIKor MEKK) which terminate(s) in the nucleus with
increases in COX-2 promoter activity mediated by
NF-B14,15. In addition, c/EBP enhancer sequences are
also believed to play a role and c/EBP/ synergize tran-
scriptionally with NF-B for full activation of the human
COX-2 promoter15,16. An alternative but less well describedFig. 7. Role of reactive oxygen species and calcium in IL-1-induced COX-2 protein synthesis. Confluent synovial fibroblasts were incubated
for 16 h at 37°C with vehicle, nimesulide (NIM, 0.3 g/ml), nifedipine (NIF, 5 mol/l), or verapamil (VER, 50 mol/l) with or without 100 pg/ml
of IL-1(A). In (B), cells were incubated for 16 h at 37°C as described in the legend (PDTC, 100 mol/l; H2O2, 100 nmol/l; NIM, 0.3 g/ml;
ionomycin (I), 10 nmol/l; thapsigargin (T), 20 nmol/l). In (C), cells were incubated for 16 h at 37°C without (Con) or with 100 pg/ml of IL-1
in the presence or absence of NIF (5 mol/l), VER (50 mol/l), PDTC (100 mol/l), or PDTC+VER. In all cases, cells were processed for
Western analysis (COX-2 protein) using 50 g of cellular protein as described in the Materials and methods section.Discussion
This study was inspired by our rather novel findings
that NSAIDs, in particular specific COX-2 inhibitors of the
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cellular calcium levels20,21 and cAMP22. Such changes can
activate calmodulin-dependent protein kinases (e.g. CaM-
KII, KIV) and protein kinase A with the resultant increases in
transcriptionally active CREB/ATF transcription factors23.
The latter are known to strongly activate COX-2 expression
via CRE sites in the proximal promoter region24,25. In
addition, there is evidence that AP-1 complexes can acti-
vate COX-2 through transactivation via CRE site (there is
no AP-1 site in the COX-2 promoter) although in the latter
studies AP-1 complexes were not IL-1 generated25,26. Our
data clearly demonstrate that the suppression of IL-1
induced-COX-2 expression by sub and therapeutic concen-
trations of NIM is not due to inhibitory effects on NF-B or
c/EBP-associated signaling cascades. It is also unlikely
that NIM acts on IL-1 induced immediate–early genes like
c-Jun/c-Fos (AP-1) since the action of NIM on COX-2
required more than 7–8 h and was most robust at 16–24 h.
IL-1 induces a number of genes (e.g. c-fos, MMP-1)
through short-lived reactive oxygen species intermediaries
which include NO, H2O2, and superoxide anion18,19. The
IL-1 stimulated increase in COX-2 gene expression in
human chondrocytes is significantly enhanced by
co-incubations with agents that raise intracellular calcium
concentrations20,21. In the present study, antioxidants
which quench either H2O2 or O2 modestly affected the
IL-1 induction of COX-2 in HSF; NO is not produced by
HSF so the issue is moot. Exogenously added H2O2 mildly
induced COX-2 which was reversed with additions of PDTC
(as expected) and NIM. The latter drug potently blocks
superanion generation in neutrophils6–8, confirming one of
its ‘allo-effects’ as a quenching agent. However, it seems
clear that IL-1 induction of COX-2 is only partially depen-
dent on ROS generation and therefore the inhibitory profile
exhibited by NIM, being more extensive than PDTC, sug-
gests that the drug can impact on other cellular responses
induced by cytokines. Important in this regard is the obser-
vation that NIM blocked ionomycin+thapsigargin-induced
COX-2 synthesis, arguing that a role for NIM in calcium
metabolism may be of some consequence. Supporting
these findings are reports showing that the drug can inhibit
calcium channel flux and intracellular accumulation of cal-
cium in different cell types27–28. The present data also
suggests that, as in chondrocytes, IL-1 stimulation of
COX-2 required at least some change in cellular calcium
metabolism. We used two inhibitors of L-type voltage-
regulated Ca+ + channels to confirm the observation,
despite their different potencies. The concentrations cho-
sen were based on our previous work and spectrofluores-
cent studies using Fura 2/AM loaded human connective
tissue cells29–31. Nifedipine is slightly more specific than
verapamil, but cannot be used at doses higher than the one
we have chosen because it induces apoptosis. Verapamil is
less toxic and therefore higher concentrations can be used
for a fuller effect.
Figure 3 clearly illustrates a relationship between PGE2
released and the level of COX-2 mRNA and protein. This
relationship is not totally unexpected but one cannot im-
mediately implicate a role for prostanoids/leukotrienes,
particularly in light of the data obtained with naproxen. The
COX-2 gene is considered an immediate–early response
gene26, and its induction by IL-1 occurs as early as
10–15 min in human connective tissue cells (MS in prep-
aration). However, traces of PGE2 are detectable after only
1–2 h, so the initial induction cannot be due to prostaglan-
din feedback. Nevertheless, products of arachidonic acidmetabolism could conceivably impact on later COX-2
expression.
In planning this study we selected our cellular (tissular)
model and biological effectors to be relevant to arthritic
diseases (e.g. OA). Indeed IL-1 is produced by resident
cells (e.g. macrophages, type A synoviocytes) of the
inflamed synovium and functions in an autocrine/paracrine
fashion, stimulating the release of a plethora of pro-
inflammatory mediators32. Lipopolysaccharide (LPS), or
endotoxin, is the major component of the outer surface of
Gram-negative bacteria and is a potent activator of cells
(macrophages/monocytes, endothelial cells, types A and B
synoviocytes) of the inflammatory response33. A minor but
potentially interesting observation in this present study was
the lack of sensitivity of HSF to LPS action at least in terms
of COX-2 synthesis and mRNA expression. Chondrocytes
are quite sensitive to LPS in this regard21, as are endo-
thelial cells and macrophages34. Since the most recent
data suggest that LPS signaling cascade uses an anal-
ogous molecular framework for signaling as IL-134, subtle
differences in IL-1 and/or LPS activated signaling path-
ways must exist between HSF and human chondrocytes
and would be an interesting subject for further exploration.
In summary, at therapeutically relevant concentrations,
NIM was shown to inhibit not only COX-2 activity but also
COX-2 expression and synthesis. At least part of this
inhibitory profile may be due to NIM effects on calcium and
ROS metabolism. Thus, our work has demonstrated
additional ‘allo-effects’ of this distinct sulfonamide class
of COX-2 specific inhibitors and points strongly to the
possibility that we may greatly enlarge their therapeutic
usefulness.Acknowledgments
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